Introduction {#s0005}
============

Deep venous thromboembolism (DVT) is a major health problem as a result of thrombosis in the deep venous of the legs ([@bb0005]). The annual incidence of DVT has been estimated between 0.1 and 0.2% of the adult population ([@bb0010]). DVT is a complicated and multi-factorial disorder which can be caused by acquired and genetic risk factors. Acquired risk factors include age, surgery, major trauma, hormone therapy, pregnancy, prolonged immobilization, plaster cast, and some types of cancer that can predispose an individual to an increased risk for DVT ([@bb0015], [@bb0020]). According to the results of family and twin studies, genetic factors account for nearly 60% of the risk for DVT ([@bb0025]).

Three major molecular mechanisms which effectively contribute to DVT are venous stasis, hypercoagulability, and blood vessel wall changes ([@bb0005], [@bb0030]). Hypercoagulability states promoting thrombosis, collectively termed "thrombophilias", may be inherited or acquired, and approximately in 40% of cases are inherited ([@bb0035]). There is much evidence that inherited thrombophilia plays a major role in thrombosis development. To date, several thrombophilic gene polymorphisms have been identified that are involved in the pathogenesis of thromboembolic disorders. Activated protein C resistance (APCR) due to the factor V (FV) G1691A polymorphism and the G20210A polymorphism in the prothrombin gene are well-characterized genetic variants causing thrombophilia. The methylentetrahydrofolate reductase (MTHFR) C677T polymorphism which causes hyperhomocysteinemia has been also considered to be a risk factor for thromboembolism ([@bb0040]). Nevertheless, these genetic variants only explain a fraction of all thromboembolic events. Therefore, it seems that there should be other genetic variants that are also involved in clot formation. [@bb0045] have reported novel polymorphisms in the factor V gene. The G4070A polymorphism in FV gene leads to an amino acid substitution His to Arg at position 1299. This polymorphism which is marked by the HR2 haplotype is associated with an increased risk for thromboembolic disease ([@bb0050]). Additionally, previous studies have reported that the increases in plasminogen activator inhibitor-1 (PAI-1) serum level could lead to a thrombotic tendency ([@bb0055], [@bb0060], [@bb0065]). The PAI-1 (− 675 I/D, 5G/4G) polymorphism affects the binding of nuclear proteins involved in the regulation of PAI-1 gene transcription. The 4G allele appears to bind only an enhancer, whereas the 5G allele binds both an enhancer and a suppressor. So, the 4G allele is associated with higher rates of PAI-1 synthesis and thromboembolism ([@bb0055]).

This study was design to determine the prevalence of FV G1691A, FV A4070G, prothrombin G20210A and PAI-1 (− 675 I/D, 5G/4G) polymorphisms in patients with DVT and healthy control, and to address the question "whether these polymorphisms are associated with DVT" by examining a large study population.

Material and methods {#s0010}
====================

Study population and inclusion criteria {#s0025}
---------------------------------------

In this case control study, 193 individuals (103 male and 90 female) with DVT clinical symptoms were selected as case group, and 500 healthy subjects (275 male and 225 female) without both personal and family histories of thromboembolic disorders were included as control group. The mean and range of age for the case and control groups were summarized in [Table 1](#t0005){ref-type="table"}. All case subjects were referred by clinician after confirmation of the existence of thrombus using Doppler ultrasonography (ALOKA, SSd-1700, Japan). Recognized environmental factors that may increase the risk of DVT, including surgery, major trauma, hospitalization, prolonged immobilization and cancer were excluded from criteria. None of the healthy control had any evidence of thrombotic events. The present study was approved by the Ethics and Human Rights Committee of Tabriz University of medical sciences, Tabriz, Iran under number 217/d/3324 and the informed consents were filled out by all participants.

DNA extraction and genotype screening {#s0030}
-------------------------------------

5 ml of peripheral blood samples were taken from all participants and genomic DNA was extracted from leukocytes using GIAamp DNA Blood Mini kit (Qiagen, USA), according to the manufacturer\'s instruction. Detections of FV G1691A, FV A4070G, prothrombin G20210A and PAI-1 (− 675 I/D, 5G/4G) polymorphisms were performed by Amplification Refractory Mutation System-PCR (ARMS-PCR) technique. Amplification of DNA was carried out using the three primer sets for each polymorphism, one forward and two reverse specific primers for the wild type and mutant alleles ([@bb0070]). PCR amplifications were performed on total volume 25 μl solution containing 100 ng genomic DNA, 1 × PCR buffer, 10 pmol of each primer, 10 nmol each deoxyribonucleotide triphosphates, 1.5 mM Mg^2 +^ and 1 U *Taq* DNA polymerase. The PCR conditions consisted of an initial denaturation step (94 °C, 2 min) was followed by 10 cycles of denaturation (94 °C, 15 s) and annealing/extension (65 °C, 60 s), followed by a final 20 cycles of denaturation (94 °C, 10 s), annealing (62 °C, 50 s), and extension (72 °C, 30 s) ([@bb0070]). The PCR products were separated on 2% agarose gel and visualized with ethidium bromide staining and UV illumination with a gel documentation system (Gel Doc 2000; Bio-Rad, Hercules, USA).

Statistical analysis {#s0035}
--------------------

Statistical analysis was performed using SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA). The Pearson\'s chi-square (*χ*^2^) and Fisher\'s exact tests were used for evaluation of genotype and allele frequencies. The homozygote and heterozygote genotypes of each group were unified as a new group and then odds ratios and 95% confidence intervals were calculated. *P* values less than 0.05 were considered statistically significant.

Results {#s0015}
=======

The genotype frequencies of the FV (G1691A and A4070G), prothrombin G20210A and PAI-1 4G/5G polymorphisms in the case and control groups were displayed in [Table 2](#t0035){ref-type="table"}. Our results showed that the frequency of FV (G1691A and A4070G) and PAI-1 4G/5G polymorphisms in the case group was significantly higher than those in healthy control group (*P* \< 0.05). Nevertheless, the frequency of prothrombin G20210A polymorphism was higher in patients with DVT than those in the healthy control group but with no significant difference (*P* \> 0.05) (see [Table 2](#t0035){ref-type="table"}).

The frequencies of the FV (G1691A and A4070G), prothrombin G20210A and PAI-1 4G/5G polymorphisms were compared between men and women subjects in each group. We found that the frequency of prothrombin G20210A and PAI-1 4G/5G polymorphisms was statistically different between men and women in the case group (*P* \< 0.05) (see [Table 3](#t0015){ref-type="table"}). We also observed that the genotype frequencies of FV G1691A and PAI-1 4G/5G polymorphisms in men of the case group were significantly higher when compared with those in healthy control groups (*P* \< 0.05) (see [Table 4](#t0020){ref-type="table"}), whereas, FV A4070G, prothrombin G20210A and PAI-1 4G/5G polymorphisms in women of the case group were significantly higher than those in healthy control (*P* \< 0.05) (see [Table 4](#t0020){ref-type="table"}).

The heterozygosity, homozygosity and mutant allele frequencies for all studied polymorphisms are given in [Table 5](#t0025){ref-type="table"}. Significant differences in mutant allele frequencies were observed between DVT patients and control groups (*P* \< 0.05) (see [Table 5](#t0025){ref-type="table"}). When the mutant allele frequencies were compared between men and/or women of cases and controls, we found that FV 1691A and PAI-1 4G alleles in men (*P* \< 0.05) and FV A4070G, prothrombin 20210A and PAI-1 4G in women of the case are statistically significant and different than those in men and women of the healthy group (*P* \< 0.05), respectively (see [Table 5](#t0025){ref-type="table"}).

Finally, When the heterozygote and homozygote genotypes of each group were unified into a new group (carrier group), and then odds ratios and 95% confidence intervals were calculated we found an association between FV G1691A and PAI-1 4G/5G gene polymorphisms and DVT (see [Table 6](#t0030){ref-type="table"}).

Discussion {#s0020}
==========

Previous literatures have discussed that thrombophilic gene polymorphisms might be related with an increased tendency for intravascular coagulation. Hence, to our best knowledge, the association between FV G1691A, FV A4070G, prothrombin G20210A, and PAI-1 (− 675 I/D, 5G/4G) polymorphisms with DVT in Northwestern Iran was investigated in the current study for the first time. Taken together, our results showed that the group with a history of DVT has an increase in the frequency of FV (G1691A and A4070G) and PAI-1 4G/5G polymorphisms when compared with healthy controls (*P* \< 0.05). However, a higher prevalence of prothrombin G20210A polymorphism was also seen in DVT patients, but did not show a statistically significant difference. These findings are in agreement with most of the previously published data.

Previous studies on FV G1691A and prothrombin G20210A polymorphisms in DVT patients proposed that both polymorphisms are major inherited risk factors associated with DVT. [@bb0075] showed that the prevalence of FV G1691A polymorphism is higher in DVT patients [@bb0075]. [@bb0080] reported that the prevalence of the FV G1691A polymorphism among patients with venous thromboembolic disease was 21.1%, compared with that in the healthy controls (5.5%) [@bb0080]. [@bb0085]. have also reported the positive association of FV G1691A polymorphism with DVT [@bb0085]. [@bb0090] found that carriers of FV G1691A and prothrombin G20210A polymorphisms have an increased risk of deep venous thrombosis [@bb0090]. Conversely, Lijfering et al reported that these polymorphisms do not have any effect on the risk of venous thrombosis ([@bb0095]). The study of [@bb0100] revealed that the frequency of prothrombin G20210A polymorphism was higher in DVT patients compared with controls, but the difference was not statistically significant [@bb0100].[@bb0105] did not find any association between prothrombin G20210A polymorphism and DVT [@bb0105].

[@bb0110] studied 126 patients who are suffering from DVT and 197 healthy controls for FV A4070G polymorphism and reported that this polymorphism had a potential role in deep venous thromboembolism [@bb0110]. In addition, [@bb0115] reported that there is an evidence to support an association of FV A4070G polymorphism with DVT [@bb0115]. Some other studies, however, suggested that there were no statistical differences in the prevalence of this polymorphism between the patient and control groups. [@bb0120] demonstrated that the prevalence of this polymorphism is similar in the case and control groups [@bb0120]. Also, these findings are consistent with the study published by [@bb0125].

In accordance with our data which shows the association of the increased risk of DVT with PAI-1 4G/5G polymorphism, there are other studies that confirm the association between this variant and venous thromboembolism. In a case--control study by [@bb0130], they indicated an association between the 4G/5G polymorphism in the promoter of the PAI-1 gene and plasma PAI-1 levels in patients with venous thromboembolism [@bb0130]. This result was confirmed by [@bb0135] who reported that the presence of the 4G allele significantly increased the risk of thrombosis in patients with thrombophilic defects [@bb0135]. [@bb0140] demonstrated that the 4G/5G polymorphism is more prevalent in patients compared with healthy controls [@bb0140]. Conversely, no differences in the frequencies of heterozygous and homozygous PAI-I polymorphism were observed when patients with DVT were compared with controls in a study by ([@bb0145]).

In conclusion, our study demonstrated that the FV (G1691A and A4070G) and PAI-1 4G/5G polymorphisms are more frequently found among patients with DVT, compared with healthy controls. This finding raises the possibility that these polymorphisms increase venous thromboembolism susceptibility.

The authors would like to express their sincerest appreciation to all individuals for participating in this study.

###### 

The mean and range of age in all studied groups.

                                         Mean age ± SD (years)   Range (years)
  -------------------------------------- ----------------------- ---------------
  Case group (n = 193)                   46.18 ± 4.72            38--57
  Control group (n = 500)                46.27 ± 5.82            36--59
  Men of the case group (n = 103)        45.38 ± 4.44            38--54
  Women of the case group (n = 90)       47.10 ± 4.89            39--57
  Men of the control group (n = 275)     45.79 ± 6.23            36--59
  Women of the control group (n = 225)   46.85 ± 5.23            37--58

Abbreviation: SD, standard deviation.

###### 

The genotype distribution of four thrombophilic gene polymorphisms in the case and control groups.

                                                              Case (n = 193)   Control (n = 500)                               
  ----------------------------------------------------------- ---------------- ------------------- ------ ------ ------ ------ -------
  FV 1691G/A[b](#tf0010){ref-type="table-fn"}                 88.6             11.4                0.0    95.8   4.2    0.0    0.001
  FV HR2 4070 A/G[c](#tf0015){ref-type="table-fn"}            89.11            9.33                1.56   94.4   5.6    0.0    0.004
  F II 20210 G/A[d](#tf0020){ref-type="table-fn"}             88.6             10.36               1.04   94     6      0.0    0.010
  PAI-1 (− 675 I/D, 5G/4G)[e](#tf0025){ref-type="table-fn"}   25.9             43                  31.1   70.6   18.2   11.2   0.000

Abbreviations: FV; Factor V, FV HR2; Factor V-His1299 Arg, F II; Factor II or Prothrombin, PAI-1; Plasminogen Activator Inhibitor-1.

*P* value calculated by chi-square test.

FV, at nucleotide position 1691 on the gene a G was exchanged by an A.

FV HR2, at nucleotide position 4070 on the gene an A was exchanged by a G.

F II, at nucleotide position 20210 on the gene a G was exchanged by an A.

PAI-1, at nucleotide position − 675 on the gene promoter a GGGGG was exchanged by a GGGG.

###### 

Comparison of genotype distribution of four thrombophilic gene polymorphisms between men and women of each group.

                                                              Case (n = 193)           Control (n = 500)                                                                                   
  ----------------------------------------------------------- ---------------- ------- ------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  FV 1691G/A[b](#tf0035){ref-type="table-fn"}                 86.4             13.60   0.0                 91.11   8.89    0.0     0.367   95.63   4.37    0.0     96      4       0.0     1.000
  FV HR2 4070 A/G[c](#tf0040){ref-type="table-fn"}            93.2             5.82    0.98                84.44   13.33   2.23    0.150   94.18   5.82    0.0     94.66   5.34    0.0     0.848
  F II 20210 G/A[d](#tf0045){ref-type="table-fn"}             95.14            4.86    0.0                 81.11   16.66   2.23    0.007   93.81   6.19    0.0     94.22   5.78    0.0     1.000
  PAI-1 (− 675 I/D, 5G/4G)[e](#tf0050){ref-type="table-fn"}   26.21            54.37   19.42               25.55   30      44.45   0.000   70.54   17.82   11.64   70.66   18.67   10.67   0.926

Abbreviations: FV; Factor V, FV HR2; Factor V-His1299 Arg, F II; Factor II or Prothrombin, PAI-1; Plasminogen Activator Inhibitor-1.

*P* value calculated by chi-square test.

FV, at nucleotide position 1691 on the gene a G was exchanged by an A.

FV HR2, at nucleotide position 4070 on the gene an A was exchanged by a G.

F II, at nucleotide position 20210 on the gene a G was exchanged by an A.

PAI-1, at nucleotide position − 675 on the gene promoter a GGGGG was exchanged by a GGGG.

###### 

Comparison of genotype distribution of four thrombophilic gene polymorphisms between men and women of the case and healthy control groups.

                                                              Men (n = 378)           Women (n = 315)                                                                                   
  ----------------------------------------------------------- --------------- ------- ----------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  FV 1691G/A[b](#tf0060){ref-type="table-fn"}                 86.4            13.6    0.0               95.63   4.37    0.0     0.005   91.11   8.89    0.0     96      4       0.0     0.099
  FV HR2 4070 A/G[c](#tf0065){ref-type="table-fn"}            93.2            5.82    0.98              94.18   5.82    0.0     0.262   84.44   13.33   2.23    94.66   5.34    0.0     0.004
  F II 20210 G/A[d](#tf0070){ref-type="table-fn"}             95.14           4.86    0.0               93.81   6.19    0.0     0.806   81.11   16.66   2.23    94.22   5.78    0.0     0.001
  PAI-1 (− 675 I/D, 5G/4G)[e](#tf0075){ref-type="table-fn"}   26.21           54.37   19.42             70.54   17.82   11.64   0.000   25.55   30      44.45   70.66   18.67   10.67   0.000

Abbreviations: FV; Factor V, FV HR2; Factor V-His1299 Arg, F II; Factor II or Prothrombin, PAI-1; Plasminogen Activator Inhibitor-1.

*P* value calculated by chi-square test.

FV, at nucleotide position 1691 on the gene a G was exchanged by an A.

FV HR2, at nucleotide position 4070 on the gene an A was exchanged by a G.

F II, at nucleotide position 20210 on the gene a G was exchanged by an A.

PAI-1, at nucleotide position − 675 on the gene promoter a GGGGG was exchanged by a GGGG.

###### 

The distribution of heterozygote and homozygote genotypes and mutant allele frequencies of the four thrombophilic gene polymorphisms in all studied groups.

                                                                Case group (n = 193)   Control group (n = 500)           Men of the case group (n = 103)   Women of the case group (n = 90)           Men of the control group (n = 275)   Women of the control group (n = 225)           Men of the case group (n = 103)   Men of the control group (n = 275)           Women of the case group (n = 90)   Women of the control group (n = 225)   
  ------------------------------------------------------------- ---------------------- ------------------------- ------- --------------------------------- ---------------------------------- ------- ------------------------------------ -------------------------------------- ------- --------------------------------- ------------------------------------ ------- ---------------------------------- -------------------------------------- -------
  *FV 1691G/A*[b](#tf0085){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                    
  GA                                                            11.40                  4.20                      0.001   13.60                             8.89                               0.367   4.37                                 4                                      1.000   13.60                             4.37                                 0.005   8.89                               4                                      0.099
  AA                                                            0.00                   0.00                      NS      0.00                              0.00                               NS      0.00                                 0.00                                   NS      0.00                              0.00                                 NS      0.00                               0.00                                   NS
  Frequency of A allele                                         5.69                   2.1                       0.001   6.79                              4.40                               0.382   2.18                                 2                                      1.000   6.79                              2.18                                 0.006   4.40                               2                                      0.103
                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  *FV HR2 4070 A/G*[c](#tf0090){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                               
  AG                                                            9.33                   3.60                      0.089   5.82                              13.33                              0.086   5.82                                 5.34                                   0.848   5.82                              5.82                                 1.000   13.33                              5.34                                   0.031
  GG                                                            1.56                   0.00                      0.021   0.98                              2.23                               0.599   0.00                                 0.00                                   NS      0.98                              0.00                                 0.272   2.23                               0.00                                   0.081
  Frequency of G allele                                         6.21                   2.8                       0.004   3.88                              8.88                               0.056   2.90                                 2.66                                   0.850   3.88                              2.90                                 0.490   8.88                               2.66                                   0.002
                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  *F II 20210 G/A*[d](#tf0095){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                
  GA                                                            10.36                  6                         0.051   4.86                              16.66                              0.009   6.19                                 5.78                                   1.000   4.86                              6.19                                 0.806   16.66                              5.78                                   0.004
  AA                                                            1.04                   0.00                      0.077   0.00                              2.23                               0.216   0.00                                 0.00                                   NS      0.00                              0.00                                 NS      2.23                               0.00                                   0.081
  Frequency of A allele                                         6.21                   3                         0.008   2.42                              10.55                              0.001   3.09                                 2.88                                   1.000   2.42                              3.09                                 0.809   10.55                              2.88                                   0.000
                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  *PAI-1 (− 675 I/D, 5G/4G)*[e](#tf0100){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                      
  5G/4G                                                         43                     18.2                      0.000   54.37                             30                                 0.001   17.82                                18.67                                  0.817   54.37                             17.82                                0.000   30                                 18.67                                  0.035
  4G/4G                                                         31.1                   11.2                      0.000   19.42                             44.45                              0.000   11.64                                10.67                                  0.777   19.42                             11.64                                0.064   44.45                              10.67                                  0.000
  Frequency of 4G allele                                        52.59                  20.3                      0.000   46.60                             59.44                              0.014   20.54                                20                                     0.535   46.60                             20.54                                0.000   59.44                              20                                     0.000

Abbreviations: FV; Factor V, FV HR2; Factor V-His1299 Arg, F II; Factor II or Prothrombin, PAI-1; Plasminogen Activator Inhibitor-1, NS; Nonsignificant.

*P* value calculated by chi-square test.

FV, at nucleotide position 1691 on the gene a G was exchanged by an A.

FV HR2, at nucleotide position 4070 on the gene an A was exchanged by a G.

F II, at nucleotide position 20210 on the gene a G was exchanged by an A.

PAI-1, at nucleotide position − 675 on the gene promoter a GGGGG was exchanged by a GGGG.

###### 

Odds ratios (95% CI) for the four thrombophilic gene polymorphisms in the case and control groups.

  Polymorphisms                                               Case (n = 193)   Control (n = 500)   *P* value[a](#tf0105){ref-type="table-fn"}   OR      95% CI           
  ----------------------------------------------------------- ---------------- ------------------- -------------------------------------------- ------- -------- ------- --------------
  FV 1691G/A[d](#tf0120){ref-type="table-fn"}                 11.40            88.60               4.20                                         95.80   0.001    0.341   0.183--0.635
  FV HR2 4070 A/G[e](#tf0125){ref-type="table-fn"}            10.88            89.12               5.60                                         94.40   0.020    0.486   0.269--0.878
  F II 20210 G/A[f](#tf0130){ref-type="table-fn"}             11.40            88.60               6.00                                         94.00   0.023    0.496   0.279--0.884
  PAI-1 (− 675 I/D, 5G/4G)[g](#tf0135){ref-type="table-fn"}   74.09            25.01               29.40                                        70.60   0.000    0.146   0.100--0.212

Abbreviations: FV; Factor V, FV HR2; Factor V-His1299 Arg, F II; Factor II or Prothrombin, PAI-1; Plasminogen Activator Inhibitor-1, OR; Odds Ratio, CI; Confidence Interval.

*P* value calculated by chi-square test.

Carriers: individuals who had either heterozygous or homozygous specified mutation.

Non-carriers: individuals who had neither heterozygous nor homozygous specified mutation.

FV, at nucleotide position 1691 on the gene a G was exchanged by an A.

FV HR2, at nucleotide position 4070 on the gene an A was exchanged by a G.

F II, at nucleotide position 20,210 on the gene a G was exchanged by an A.

PAI-1, at nucleotide position − 675 on the gene promoter a GGGGG was exchanged by a GGGG.
